Victory Capital Management
MNPR icon

Victory Capital Management’s Monopar Therapeutics MNPR Stock Holding History

Victory Capital Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-69
Closed -$2K – 2964
2020
Q1 		$2K Buy
+69
New +$4.32K ﹤0.01% 3514

Other funds holding MNPR

Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Victory Capital Management's MNPR Position: Q2 2020 in Review

Victory Capital Management sold out of Monopar Therapeutics (MNPR) in Q2 2020, closing a stake of 69 shares — an estimated $2K sold.

Victory Capital Management first reported a position in MNPR in Q1 2020 and held it in 1 quarter. The position peaked at $2K in Q1 2020. 5 funds tracked by Wall St. Rank hold MNPR as of Q2 2020.

  • Victory Capital Management reported no remaining Monopar Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 69 Monopar Therapeutics shares in Q2 2020, an estimated $2K.
  • Victory Capital Management first reported a position in Monopar Therapeutics in Q1 2020 and held it in 1 quarter.
  • Victory Capital Management's Monopar Therapeutics position peaked at $2K in Q1 2020.
  • 5 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.